bluemason3 said:She mentioned in a private chat that she came across some psychiatrists on various forums who argued that those old-school tricyclic antidepressants were actually more effective than the SSRIs we see everywhere today. Apparently, while the older stuff comes with its own set of nasty side effects, the push for newer meds is largely driven by the bottom line—big pharma pushes the latest drugs because they still hold the patents, whereas the generics don't bring in nearly as much cash.
??? 🤷 🤔 :teorijezavjereito: 😁
Patient care requires an individualized approach; some respond better to tricyclics, while others require SSRIs. A patent lasts for its designated term—typically 20 years—after which generics can be produced. The number of times the original brand-name drug was prescribed has no bearing on that process.🤷 Generally speaking, many psychiatrists prefer prescribing brand-name medications over generics.
bluemason3 said:It’s also true that under the new transparency laws here in the US, they were forced to release some research they had been dodging for years. Apparently, it shows SSRIs are basically just fancy placebos—they might make you feel like something is happening, but they don't actually have any measurable impact on depression itself. So, you're just left with side effects that create a stronger placebo sensation, while the actual depressive symptoms stay exactly where they were. 🤷
Anyway, that's just what I heard. Does anyone actually know the specifics of what this study is about?
What kind of act is that?🤷
Can you provide the link to that study? Otherwise, Americans have research claiming vaccines cause autism, yet they also have studies claiming they don't. One must be cautious with research.😁
bluemason3 said:I also heard recently—before it was even official—that some independent study on antipsychotics suggested the older generations of meds actually yielded better results 🤔
It depends on the specific parameters involved. While older antipsychotics offer certain advantages, they are frequently criticized for lacking a "neuroprotective effect." When used alongside schizophrenia, they can still lead to neurodegeneration. Conversely, newer antipsychotics provide that neuroprotection, yet they face backlash due to increased appetite, which leads to significant weight gain and metabolic syndrome.
The standard procedure is to prioritize scheduling the newer AP units first; if they aren't available, we move on to the older ones.